Company intelligence / Profile preview
Vela Pharmaceuticals
Iselin/Lawrenceville, New Jersey, USAveladx.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Vela Pharmaceuticals was a privately held biotech/pharma company focused on developing medicines targeting diseases of the nervous system, especially those involving the brain-gut axis. Its lead asset, R-tofisopam, showed positive Phase II results in irritable bowel syndrome. The company also had assets targeting depression and additional preclinical candidates. In March–April 2006 it was acquired by Pharmos Corporation in a deal valued at approximately $29.7 million.
- Therapeutic areas
- GastroenterologyPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Otsuka Pharmaceutical Co., Ltd.
Beyond the preview
Go deeper on Vela Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vela Pharmaceuticals.